Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6151874 | 0.86 | MAPT (0.71) | MAPTHSP90AA1ALDH1A1RECQLKMT2A | |
| Bromide SCHEMBL11257226 | 0.85 | MAPT (0.78) | MAPTHSP90AA1ALDH1A1KMT2AATM | |
| Hydrochloric Acid SCHEMBL2770300 | 0.81 | NPSR1 (0.71) | MAPTHSP90AA1KMT2AATMNPSR1 | |
| Hydrochloric Acid SCHEMBL3072623 | 0.80 | HSP90AA1 (0.64) | MAPTHSP90AA1KMT2AATMNPSR1 | |
| Hydrochloric Acid SCHEMBL10416961 | 0.80 | KDM4E (0.65) | MAPTALDH1A1KMT2AATMPABPC1 | |
| Hydrochloric Acid SCHEMBL10705383 | 0.79 | KDM4E (0.63) | MAPTALDH1A1KMT2AATMPABPC1 | |
| Bromide SCHEMBL5148045 | 0.78 | NPSR1 (0.71) | MAPTHSP90AA1ALDH1A1KMT2AATM | |
| Fluoride Ion SCHEMBL5149111 | 0.78 | NPSR1 (0.71) | MAPTHSP90AA1ALDH1A1KMT2AATM | |
| SCHEMBL5430523 | 0.78 | MAPT (0.63) | MAPTHSP90AA1KMT2AATMNPSR1 | |
| SCHEMBL16810262 | 0.78 | KDM4E (0.67) | MAPTALDH1A1KMT2AATMPABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355645-A4 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | ALTEON INC (US) | 2005-02-23 | — | — | EP | claimed |
| US-20040097495-A1 | Method for treating fibrotic diseases or other indications IIIC | WAGLE DILIP (US) | 2004-05-20 | — | — | US | claimed |
| EP-1355645-A2 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | Alteon, Inc. (US) | 2003-10-29 | — | — | EP | claimed |
| US-20020183365-A1 | Method for treating fibrotic diseases or other indications IIIC | ALTEON, INC. | 2002-12-05 | — | — | US | claimed |
| WO-2002067851-A2 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | ALTEON, INC. (US) | 2002-09-06 | — | — | WO | claimed |
| EP-1355645-A4 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | ALTEON INC (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040097495-A1 | Method for treating fibrotic diseases or other indications IIIC | WAGLE DILIP (US) | 2004-05-20 | — | — | US | disclosed |
| EP-1355645-A2 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | Alteon, Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20020183365-A1 | Method for treating fibrotic diseases or other indications IIIC | ALTEON, INC. | 2002-12-05 | — | — | US | disclosed |
| WO-2002067851-A2 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | ALTEON, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097495-A1 | Method for treating fibrotic diseases or other indications IIIC | COL1A1, COL2A1, MMP1 | MAPT 3619/4885HSP90AA1 1118/4885ALDH1A1 844/4885 |
| US-20020183365-A1 | Method for treating fibrotic diseases or other indications IIIC | EPX, COL2A1, COL1A1 | MAPT 4558/4885HSP90AA1 1064/4885ALDH1A1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.